Case Control Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2021; 13(12): 2071-2080
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2071
Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis
Jarosław Jerzy Sak, Andrzej Prystupa, Paweł Kiciński, Dorota Luchowska-Kocot, Ewa Kurys-Denis, Hanna Bis-Wencel
Jarosław Jerzy Sak, Chair and Department of Humanities and Social Medicine, Medical University of Lublin, Lublin 20-093, Poland
Andrzej Prystupa, Department of Internal Medicine, Medical University of Lublin, Lublin 20-081, Poland
Paweł Kiciński, Department of Experimental Hematooncology, Medical University of Lublin, Lublin 20-080, Poland
Dorota Luchowska-Kocot, Department of Medical Chemistry, Medical University of Lublin, Lublin 20-093, Poland
Ewa Kurys-Denis, The Second Department of Radiology, Medical University of Lublin, Lublin 20-081, Poland
Hanna Bis-Wencel, Department of Microbiology and Reproductive Biology, University of Life Sciences in Lublin, Lublin 20-950, Poland
Author contributions: Sak JJ and Prystupa A were involved in the conception of the study, data collection and analysis, drafting and revision of the manuscript; Kiciński P and Luchowska-Kocot D were involved in the data collection and analysis; Kurys-Denis E was involved in the drafting and revision of the manuscript; Bis-Wencel H contributed to the data collection and revision of the manuscript.
Supported by the Grant from the Medical University of Lublin, No. DS 507/2013–2015.
Institutional review board statement: The study protocol was approved by the Bioethics Committee at Medical University of Lublin, Poland.
Informed consent statement: All patients gave their written informed consent for participation in the study.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Jarosław Jerzy Sak, MD, PhD, Academic Research, Additional Professor, Director, Chair and Department of Humanities and Social Medicine, Medical University of Lublin, ul. Chodźki 7 (Collegium Academicum), Lublin 20-093, Poland.
Received: January 4, 2021
Peer-review started: January 4, 2021
First decision: July 8, 2021
Revised: July 22, 2021
Accepted: November 24, 2021
Article in press: November 24, 2021
Published online: December 27, 2021
Core Tip

Core Tip: Leukocyte cell-derived chemotaxin-2 (LECT2) was first described in 1996 as a novel chemotactic factor for neutrophils. It has been widely studied to determine its usefulness for monitoring the course of non-alcoholic fatty liver disease but not for alcoholic liver cirrhosis (ALC). We suggest that LECT2 may be used for the non-invasive diagnosis of ALC.